{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:15:21Z","timestamp":1791112521587,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8,1]]},"DOI":"10.1093\/cid\/ciu234","type":"journal-article","created":{"date-parts":[[2014,4,12]],"date-time":"2014-04-12T03:27:24Z","timestamp":1397273244000},"page":"425-434","source":"Crossref","is-referenced-by-count":54,"title":["Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1\u2013Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE Trials"],"prefix":"10.1093","volume":"59","author":[{"given":"Pablo","family":"Tebas","sequence":"first","affiliation":[{"name":"University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sension","sequence":"additional","affiliation":[{"name":"Comprehensive Care Center, Fort Lauderdale, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Arribas","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, IdiPAZ, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Duiculescu","sequence":"additional","affiliation":[{"name":"Titu Maiorescu University of Medicine and Dr Victor Babes Hospital for Infectious and Tropical Diseases, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Florence","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine, Antwerp"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Wilkin","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Vanveggel","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases BVBA, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Stevens","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases BVBA, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Deckx","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases BVBA, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ECHO and THRIVE Study Groups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,4,11]]},"reference":[{"key":"key\n\t\t\t\t20180328172019_CIU234C1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-na\u00efve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328172019_CIU234C2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-na\u00efve adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328172019_CIU234C3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0b013e31824d006e","article-title":"Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-na\u00efve, HIV-1-infected patients: pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials","volume":"60","author":"Cohen","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328172019_CIU234C4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0b013e32835cee6e","article-title":"Week 96 efficacy and safety of rilpivirine in treatment-na\u00efve, HIV-1 patients in two phase III randomized trials","volume":"27","author":"Cohen","year":"2013","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328172019_CIU234C5","article-title":"Edurant\u00ae (rilpivirine) [tablets]. Full prescribing information. Janssen-Cilag, 2014"},{"key":"key\n\t\t\t\t20180328172019_CIU234C6","article-title":"Edurant\u00ae (rilpivirine) tablets, EU summary of product characteristics. Janssen-Cilag, February 2013"},{"key":"key\n\t\t\t\t20180328172019_CIU234C7","article-title":"COMPLERA\u2122 (emtricitabine\/rilpivirine\/tenofovir disoproxil fumarate) tablets"},{"key":"key\n\t\t\t\t20180328172019_CIU234C8","article-title":"EVIPLERA 200 mg\/25 mg\/245 mg film-coated tablets. Summary of Product Characteristics"},{"key":"key\n\t\t\t\t20180328172019_CIU234C9","article-title":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. 1\u2013239 (updated February 2013)"},{"key":"key\n\t\t\t\t20180328172019_CIU234C10","article-title":"EACS guidelines: EACS European Guidelines for treatment of HIV infected adults in Europe"},{"key":"key\n\t\t\t\t20180328172019_CIU234C11","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","article-title":"Clinical assessment of HIV-associated lipodystrophy in an ambulatory population","volume":"15","author":"Lichtenstein","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328172019_CIU234C12","first-page":"49","article-title":"Dyslipidemia related to antiretroviral therapy","volume":"13","author":"Estrada","year":"2011","journal-title":"AIDS Rev"},{"key":"key\n\t\t\t\t20180328172019_CIU234C13","first-page":"112","article-title":"Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy","volume":"14","author":"Domingo","year":"2012","journal-title":"AIDS Rev"},{"key":"key\n\t\t\t\t20180328172019_CIU234C14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328172019_CIU234C15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/met.2008.0096","article-title":"Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease","volume":"7","author":"Anuurad","year":"2009","journal-title":"Metab Syndr Relat Disord"},{"key":"key\n\t\t\t\t20180328172019_CIU234C16","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","article-title":"Cardiovascular disease risk factors in HIV patients\u2014association with antiretroviral therapy: results from the DAD study","volume":"17","author":"Friis-M\u00f8ller","year":"2003","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328172019_CIU234C17","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1097\/QAD.0b013e32834917c6","article-title":"Elevated triglycerides and risk of myocardial infarction in HIV-positive persons","volume":"25","author":"Worm","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328172019_CIU234C18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0192623308327119","article-title":"The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications","volume":"37","author":"Flint","year":"2009","journal-title":"Toxicol Pathol"},{"key":"key\n\t\t\t\t20180328172019_CIU234C19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0b013e328341f925","article-title":"Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care","volume":"24","author":"Crane","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328172019_CIU234C20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/649897","article-title":"Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study","volume":"201","author":"Worm","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328172019_CIU234C21","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/jac\/dkq507","article-title":"Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens","volume":"66","author":"Maggi","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328172019_CIU234C22","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Friis-M\u00f8ller","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328172019_CIU234C23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/QAD.0b013e32835b2ef1","article-title":"Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events","volume":"27","author":"Monforte","year":"2013","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328172019_CIU234C24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00002030-200007070-00002","article-title":"Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection","volume":"14","author":"Mallal","year":"2000","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328172019_CIU234C25","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/archinte.160.13.2050","article-title":"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study","volume":"160","author":"Tsiodras","year":"2000","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20180328172019_CIU234C26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/jac\/dkn191","article-title":"The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy","volume":"62","author":"P\u00e9rez-Molina","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328172019_CIU234C27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/QAD.0b013e32832b4377","article-title":"Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment","volume":"23","author":"Haubrich","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328172019_CIU234C28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"key\n\t\t\t\t20180328172019_CIU234C29","article-title":"Division of AIDS table for grading the severity of adult and pediatric adverse events"},{"key":"key\n\t\t\t\t20180328172019_CIU234C30","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328172019_CIU234C31","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180328172019_CIU234C32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328172019_CIU234C33","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-na\u00efve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328172019_CIU234C34","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","article-title":"Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy","volume":"361","author":"Sax","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328172019_CIU234C35","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0010019","article-title":"Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-na\u00efve patients infected with HIV-1","volume":"1","author":"van Leth","year":"2004","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20180328172019_CIU234C36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/135965350501000511","article-title":"Lipid profiles for antiretroviral-na\u00efve patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study","volume":"10","author":"Young","year":"2005","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180328172019_CIU234C37","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/jac\/dkr533","article-title":"Lipid profiles for etravirine versus efavirenz in treatment-na\u00efve patients in the randomized, double-blind SENSE trial","volume":"67","author":"F\u00e4tkenheuer","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328172019_CIU234C38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2174\/1874192401105010049","article-title":"HIV and HAART-associated dyslipidemia","volume":"5","author":"Feeney","year":"2011","journal-title":"Open Cardiovasc Med J"},{"key":"key\n\t\t\t\t20180328172019_CIU234C39","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1086\/589622","article-title":"A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy","volume":"198","author":"Cameron","year":"2008","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328172019_CIU234C40","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/QAI.0b013e3181142d26","article-title":"Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. dual x-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384","volume":"45","author":"Dub\u00e9","year":"2007","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/59\/3\/425\/17351867\/ciu234.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T02:19:54Z","timestamp":1689128394000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/59\/3\/425\/2895310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,11]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,4,11]]},"published-print":{"date-parts":[[2014,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciu234","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,11]]}}}